ArticleEuropean stroke journal2026
Characterisation of patients with intracerebral haemorrhage with mixed location haemorrhages: clinical and imaging features, CSF neurodegeneration markers and recurrence risk.
Article in European stroke journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe most frequent causes of ICH include arteriolosclerotic small vessel disease (aSVD-ICH) and cerebral amyloid angiopathy (CAA-ICH). The predominant underlying pathology and natural history of ICH patients with mixed deep and lobar location haemorrhages (MLH-ICH) remain insufficiently studied. PATIENTS AND
methodsWe performed a retrospective analysis of consecutive patients with ICH admitted between 2018 and 2024 and selected patients without macrostructural cause of haemorrhage, with available magnetic resonance imaging. We compared clinical characteristics, imaging markers, cerebrospinal fluid (CSF) neurodegeneration markers and ICH recurrence in patients with CAA-ICH, MLH-ICH and aSVD-ICH.
resultsWe included 217 patients (CAA-ICH = 87, MLH-ICH = 79, aSVD-ICH = 51), median age was 72 years (IQR = 60-79), and 85 patients were female (39.2%). Patients with MLH-ICH were younger than CAA-ICH patients (P = .009) but older than aSVD-ICH patients (P = .012). Absence of cortical superficial siderosis, absence of severe burden of enlarged perivascular spaces (EPVS) in the centrum semiovale, presence of severe burden of EPVS in the basal ganglia, presence of deep and lobar cerebellar microbleeds and presence of deep lacunes were independently associated with MLH-ICH. Patients with MLH-ICH had higher CSF amyloid β42 (median 719 vs 359 pg/mL, P < .001) and amyloid β40 levels (median 9124 vs 6958 pg/mL, P = .010) than CAA-ICH patients. ICH recurrence was higher in CAA-ICH (10.0 per 100 person-years), followed by MLH-ICH (6.0 per 100 person-years) and aSVD-ICH (1.3 per 100 person-years) (P = .048). DISCUSSION AND
conclusionsNeuroimaging features, CSF neurodegeneration markers and ICH recurrence risk suggest that CAA is not the predominant pathology in most cases of MLH-ICH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.